COMMUNIQUÉS West-GlobeNewswire

-
Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association
03/04/2024 -
MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures
03/04/2024 -
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/04/2024 -
Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference
03/04/2024 -
QIAGEN strengthens its portfolio for cancer research, showcasing latest product launches at AACR Annual Meeting 2024
03/04/2024 -
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
03/04/2024 -
Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
03/04/2024 -
Nkarta to Participate in Upcoming Investor Conferences
03/04/2024 -
Standard BioTools Announces Multi-Year Strategic Engagement with Bristol Myers Squibb for Use of the SomaScan® Platform for Translational Medicine Research
03/04/2024 -
Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F
03/04/2024 -
Inventiva annonce le dépôt de son Document d’Enregistrement Universel 2023 et de son Rapport Annuel 2023 (« Form 20-F »)
03/04/2024 -
Two Legend Senior Living® Directors Receive Prestigious Hero Awards From the Texas Assisted Living Association (TALA)
03/04/2024 -
Merus participera à une discussion informelle lors de la 23e conférence annuelle Needham Virtual Healthcare
03/04/2024 -
UPDATE – Redhook Brewery Announces New “Big Juicy Ballard” IPA and Revives IPA Daze Festival at the Brewlab on 4/20 Weekend
03/04/2024 -
NH Nonprofit Heralds New Research Documenting Community Healthcare Workers
03/04/2024 -
IBEX Shareholders Approve Sale of the Company
03/04/2024 -
CARBIOS annonce le vif succès de son premier plan d'actionnariat salarié
03/04/2024 -
AB Science announces that Health Canada has granted eligibility for reconsideration request for masitinib in ALS
03/04/2024 -
AB Science annonce que Santé Canada a jugé admissible la demande de réexamen du masitinib dans SLA
03/04/2024
Pages